287 related articles for article (PubMed ID: 16825203)
21. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
Stip E; Tourjman V
Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
[TBL] [Abstract][Full Text] [Related]
22. Antipsychotic monotherapy and adjuvant psychotropic therapies in schizophrenia patients: effect on time to readmission.
Valevski A; Gilat Y; Olfson M; Benaroya-Milshtein N; Weizman A
Int Clin Psychopharmacol; 2012 May; 27(3):159-64. PubMed ID: 22466059
[TBL] [Abstract][Full Text] [Related]
23. Comparison of treatment discontinuation and hospitalization among nonadherent patients initiating depot or oral typical antipsychotic medications.
Novick D; Haro JM; Bertsch J; Anand H; Jemiai N; Haddad PM
Int Clin Psychopharmacol; 2012 Sep; 27(5):275-82. PubMed ID: 22699789
[TBL] [Abstract][Full Text] [Related]
24. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
Houthoofd SA; Morrens M; Sabbe BG
Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
[TBL] [Abstract][Full Text] [Related]
25. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study.
De Hert M; Correll CU; Cohen D
Schizophr Res; 2010 Mar; 117(1):68-74. PubMed ID: 20060684
[TBL] [Abstract][Full Text] [Related]
26. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary.
Katona L; Czobor P; Bitter I
Schizophr Res; 2014 Jan; 152(1):246-54. PubMed ID: 24275583
[TBL] [Abstract][Full Text] [Related]
27. Higher serum concentrations of tyrosine and glutamate in schizophrenia patients treated with clozapine, compared to in those treated with conventional antipsychotics.
Melkersson K; Lewitt M; Hall K
Neuro Endocrinol Lett; 2015; 36(5):465-80. PubMed ID: 26707048
[TBL] [Abstract][Full Text] [Related]
28. Antipsychotic prescription filling in patients with schizophrenia or schizoaffective disorder.
Reutfors J; Brandt L; Stephansson O; Kieler H; Andersen M; Bodén R
J Clin Psychopharmacol; 2013 Dec; 33(6):759-65. PubMed ID: 24126686
[TBL] [Abstract][Full Text] [Related]
29. Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapine.
Kesserwani J; Kadra G; Downs J; Shetty H; MacCabe JH; Taylor D; Stewart R; Chang CK; Hayes RD
J Psychopharmacol; 2019 Apr; 33(4):449-458. PubMed ID: 30616489
[TBL] [Abstract][Full Text] [Related]
30. Correlates of rehospitalisation in schizophrenia.
Dey S; Menkes DB; Obertova Z; Chaudhuri S; Mellsop G
Australas Psychiatry; 2016 Aug; 24(4):356-9. PubMed ID: 26906441
[TBL] [Abstract][Full Text] [Related]
31. Psychiatric hospital utilization in patients treated with clozapine for up to 4.5 years in a state mental health care system.
Reid WH; Mason M
J Clin Psychiatry; 1998 Apr; 59(4):189-94. PubMed ID: 9590670
[TBL] [Abstract][Full Text] [Related]
32. Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study.
Solmi M; Tiihonen J; Lähteenvuo M; Tanskanen A; Correll CU; Taipale H
Schizophr Bull; 2022 Jan; 48(1):166-175. PubMed ID: 34286338
[TBL] [Abstract][Full Text] [Related]
33. Comparative Effectiveness of Clozapine and Standard Antipsychotic Treatment in Adults With Schizophrenia.
Stroup TS; Gerhard T; Crystal S; Huang C; Olfson M
Am J Psychiatry; 2016 Feb; 173(2):166-73. PubMed ID: 26541815
[TBL] [Abstract][Full Text] [Related]
34. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia.
Tiihonen J; Taipale H; Mehtälä J; Vattulainen P; Correll CU; Tanskanen A
JAMA Psychiatry; 2019 May; 76(5):499-507. PubMed ID: 30785608
[TBL] [Abstract][Full Text] [Related]
35. Antipsychotics and mortality in first-onset schizophrenia: prospective Finnish register study with 5-year follow-up.
Kiviniemi M; Suvisaari J; Koivumaa-Honkanen H; Häkkinen U; Isohanni M; Hakko H
Schizophr Res; 2013 Oct; 150(1):274-80. PubMed ID: 23953217
[TBL] [Abstract][Full Text] [Related]
36. Long-term persistence of the risk of agranulocytosis with clozapine compared with other antipsychotics: a nationwide cohort and case-control study in Finland.
Rubio JM; Kane JM; Tanskanen A; Tiihonen J; Taipale H
Lancet Psychiatry; 2024 Jun; 11(6):443-450. PubMed ID: 38697177
[TBL] [Abstract][Full Text] [Related]
37. Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study.
Taipale H; Tanskanen A; Correll CU; Tiihonen J
Lancet Psychiatry; 2022 Apr; 9(4):271-279. PubMed ID: 35182475
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological treatments and risk of readmission to hospital for unipolar depression in Finland: a nationwide cohort study.
Tiihonen J; Tanskanen A; Hoti F; Vattulainen P; Taipale H; Mehtälä J; Lähteenvuo M
Lancet Psychiatry; 2017 Jul; 4(7):547-553. PubMed ID: 28578901
[TBL] [Abstract][Full Text] [Related]
39. Electronically monitored adherence in outpatients with schizophrenia or schizoaffective disorder: a comparison of first- vs. second-generation antipsychotics.
Nakonezny PA; Byerly MJ
Schizophr Res; 2006 Feb; 82(1):107-14. PubMed ID: 16376522
[TBL] [Abstract][Full Text] [Related]
40. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics.
Csernansky JG; Schuchart EK
CNS Drugs; 2002; 16(7):473-84. PubMed ID: 12056922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
